Heron Sues Fresenius to Block Copies of Cinvanti Moneymaker (1)

Heron Therapeutics Inc. alleges that a generic version of Cinvanti proposed by Fresenius SE & Co. infringes nine patents for the injection, used to treat nausea and vomiting from cancer chemotherapy and the source of nearly all of Heron’s revenue, according to a federal lawsuit in Delaware.

Fresenius subsidiaries Fresenius Kabi AG and Fresenius Kabi USA LLC want to sell a generic version of Cinvanti’s injectable emulsion containing 130 miligrams of the drug’s active ingredient, aprepitant, per 18 milliliters, according to a complaint filed Thursday in the US District Court for the District of Delaware.

The US Food and Drug ...